$RSPI
RespireRx Pharmaceuticals Inc.

2023 Q1 Form 10-Q Financial Statement

#000149315223018545 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $292.0K $495.8K
YoY Change -41.11% -23.18%
% of Gross Profit
Research & Development $98.43K $121.2K
YoY Change -18.76% -21.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $390.4K $617.0K
YoY Change -36.73% -22.89%
Operating Profit -$390.4K -$617.0K
YoY Change -36.73%
Interest Expense $67.27K -$243.2K
YoY Change -127.66% 385.35%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$430.1K -$860.2K
YoY Change -50.0% 1.17%
Income Tax
% Of Pretax Income
Net Earnings -$430.1K -$860.2K
YoY Change -50.0% 1.17%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share $0.00 -$8.787K
COMMON SHARES
Basic Shares Outstanding 137.2M shares 97.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.00 $250.00
YoY Change -44.0% -95.33%
Cash & Equivalents $138.00 $250.00
Short-Term Investments
Other Short-Term Assets $95.75K $103.1K
YoY Change -7.11% 2.79%
Inventory
Prepaid Expenses $95.75K
Receivables
Other Receivables
Total Short-Term Assets $95.89K $103.3K
YoY Change -7.2% -2.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $95.89K $103.3K
Total Long-Term Assets $0.00 $0.00
Total Assets $95.89K $103.3K
YoY Change -7.2% -2.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.952M $5.479M
YoY Change 8.62% 8.14%
Accrued Expenses $3.481M $2.789M
YoY Change 24.84% 44.18%
Deferred Revenue
YoY Change
Short-Term Debt $2.854M $2.439M
YoY Change 17.0% 56.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.29M $10.71M
YoY Change 14.76% 25.08%
LONG-TERM LIABILITIES
Long-Term Debt $119.0K $264.0K
YoY Change -54.92%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $119.0K $264.0K
YoY Change -54.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.29M $10.71M
Total Long-Term Liabilities $119.0K $264.0K
Total Liabilities $12.41M $10.97M
YoY Change 13.08% 28.17%
SHAREHOLDERS EQUITY
Retained Earnings -$176.5M
YoY Change
Common Stock $144.3K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.31M -$10.87M
YoY Change
Total Liabilities & Shareholders Equity $95.89K $103.3K
YoY Change -7.2% -2.18%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$430.1K -$860.2K
YoY Change -50.0% 1.17%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$29.19K -$23.13K
YoY Change 26.19% -91.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $29.24K 21.99K
YoY Change 32.96% -92.45%
NET CHANGE
Cash From Operating Activities -$29.19K -23.13K
Cash From Investing Activities
Cash From Financing Activities $29.24K 21.99K
Net Change In Cash $50.00 -1.140K
YoY Change -104.39% -125.22%
FREE CASH FLOW
Cash From Operating Activities -$29.19K -$23.13K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000849636
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 RSPI Stock Issued During Period Value Issuance Of Common Stock Upon Cashless Warrant Exercise
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponCashlessWarrantExercise
usd
CY2023Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
usd
CY2022Q1 RSPI Cashless Warrant Exercises
CashlessWarrantExercises
usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2023Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2023Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2022Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2022Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Weighted Average Exercise Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
1-16467
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
RESPIRERX PHARMACEUTICALS INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0303583
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
126 Valley Road
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite C
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Glen Rock
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07452
CY2023Q1 dei City Area Code
CityAreaCode
(201)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
444-4947
CY2023Q1 dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Not applicable
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
157026672 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
95749 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
22693 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
95887 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22781 usd
CY2023Q1 us-gaap Assets
Assets
95887 usd
CY2022Q4 us-gaap Assets
Assets
22781 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5952016 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5724390 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3481308 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3296008 usd
CY2023Q1 RSPI Convertible Note Payable Current
ConvertibleNotePayableCurrent
1300278 usd
CY2022Q4 RSPI Convertible Note Payable Current
ConvertibleNotePayableCurrent
1258315 usd
CY2023Q1 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
96408 usd
CY2022Q4 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
15847 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12287270 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11729101 usd
CY2023Q1 us-gaap Accounts Payable Interest Bearing Noncurrent
AccountsPayableInterestBearingNoncurrent
119000 usd
CY2022Q4 us-gaap Accounts Payable Interest Bearing Noncurrent
AccountsPayableInterestBearingNoncurrent
174000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
119000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
174000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
12406270 usd
CY2022Q4 us-gaap Liabilities
Liabilities
11903101 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
21703 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
21703 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
144326672 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144326672 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125544276 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125544276 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
144327 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
125544 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164011506 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164030289 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176487919 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-176057856 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-12310383 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11880320 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95887 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22781 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
291949 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
495793 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98425 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
121159 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
390374 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
616952 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-390374 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-616952 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
67272 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
259647 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27583 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
16436 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-430063 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-860163 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137182491 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97894276 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11880320 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-430063 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-12310383 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10007758 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-10007758 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-860163 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-10867921 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-10867921 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-430063 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-860163 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6540 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
209772 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
27583 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
16436 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-177883 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7502 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-22227 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
172626 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
213719 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
185300 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
179800 usd
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
56490 usd
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
50065 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29188 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23133 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
29238 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
21987 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29238 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21987 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1146 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1398 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
138 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
252 usd
CY2023Q1 RSPI Cashless Warrant Exercises
CashlessWarrantExercises
18783 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
2341 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1712 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-430063 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2102720 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3972993 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29188 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-143905 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-12310383 usd
CY2023Q1 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
maturity dates that range from April 14, 2023 to May 31, 2023
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zj9iwXigbGe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zZL90zWuzzf9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
395383183 shares
CY2023Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0076
CY2023Q1 RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y2M1D
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0039
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zEMYEfadu3Kl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zRSbzy20WYd8">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0718
CY2022Q1 RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y26D
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2023Q1 us-gaap Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend
IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
<p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend_z0OvSHSOMmI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zkrxtb4ipogk">Patent Costs</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1065762525 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
124899200 shares
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zgBQFqDvA4Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zxafeYN4xxm6">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain comparative figures in 2022 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 RSPI Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3504424 shares
CY2022Q4 RSPI Preferred Stock Shares Undesignated
PreferredStockSharesUndesignated
3504424 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144326672 shares
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
776233719 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
419683183 shares
CY2022Q4 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0074
CY2022 RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M10D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
24300000 shares
CY2023Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Issued Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised
0.0015
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
59420298 shares
CY2021Q4 RSPI Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice
0.0718
CY2021 RSPI Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
59420298 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9199356 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.592
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M26D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9199356 shares
CY2023Q1 RSPI Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
0.592
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y8M26D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
9199356 shares
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
9199356 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
144326672 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144326672 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9199356 shares
CY2023Q1 RSPI Debt Conversion Shares Issuable
DebtConversionSharesIssuable
661179985 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
395383183 shares
CY2021Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
75000 usd
CY2021Q3 RSPI Agreement Expiration Date
AgreementExpirationDate
2022-06-30
CY2023Q1 RSPI Commercial Sale Of Product
CommercialSaleOfProduct
350000 usd
CY2023Q1 us-gaap Contractual Obligation
ContractualObligation
423285 usd
CY2023Q1 us-gaap Contractual Obligation
ContractualObligation
423285 usd
CY2023Q1 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
368285 usd
CY2023Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
10000 usd
CY2023Q1 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
15000 usd
CY2023Q1 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
15000 usd
CY2023Q1 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
15.0000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001493152-23-018545-index-headers.html Edgar Link pending
0001493152-23-018545-index.html Edgar Link pending
0001493152-23-018545.txt Edgar Link pending
0001493152-23-018545-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rspi-20230331.xsd Edgar Link pending
Show.js Edgar Link pending
rspi-20230331_cal.xml Edgar Link unprocessable
rspi-20230331_def.xml Edgar Link unprocessable
rspi-20230331_lab.xml Edgar Link unprocessable
rspi-20230331_pre.xml Edgar Link unprocessable